Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Depreciation and Depletion: 2015-2025

Historic Depreciation and Depletion for Voyager Therapeutics (VYGR) over the last 11 years, with Sep 2025 value amounting to $932,000.

  • Voyager Therapeutics' Depreciation and Depletion fell 17.67% to $932,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 20.44%. This contributed to the annual value of $4.7 million for FY2024, which is 6.53% up from last year.
  • As of Q3 2025, Voyager Therapeutics' Depreciation and Depletion stood at $932,000, which was down 12.49% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Depreciation and Depletion registered a high of $2.8 million during Q1 2022, and its lowest value of $843,000 during Q4 2022.
  • Its 3-year average for Depreciation and Depletion is $1.1 million, with a median of $1.1 million in 2023.
  • As far as peak fluctuations go, Voyager Therapeutics' Depreciation and Depletion surged by 120.72% in 2022, and later slumped by 61.77% in 2023.
  • Quarterly analysis of 5 years shows Voyager Therapeutics' Depreciation and Depletion stood at $1.5 million in 2021, then tumbled by 44.43% to $843,000 in 2022, then soared by 58.36% to $1.3 million in 2023, then fell by 24.27% to $1.0 million in 2024, then fell by 17.67% to $932,000 in 2025.
  • Its last three reported values are $932,000 in Q3 2025, $1.1 million for Q2 2025, and $1.0 million during Q1 2025.